Cost-effectiveness of biological therapy in remission induction of moderate to severe plaque psoriasis

Dermatology

Volumn 221, Issue 3, 2010, Pages 236-242

  Schmitt Rau, K ^a,b   Rosenbach, T ^c   Radtke, M A ^a   Augustin, M ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b Sr Healthcare Management Consulting   (Germany)

^c Private Practice   (Germany)

Author keywords

Biological agents; Cost effectiveness; Plaque type psoriasis

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB; PLACEBO; USTEKINUMAB;

ADULT; ARTICLE; BIOLOGICAL THERAPY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; DRUG COST; DRUG EFFICACY; FEMALE; GERMANY; HEALTH CARE COST; HEALTH CARE SYSTEM; HUMAN; LITERATURE; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MEDICAL FEE; PRIORITY JOURNAL; PSORIASIS VULGARIS; REMISSION; SENSITIVITY ANALYSIS;

ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; COST-BENEFIT ANALYSIS; GERMANY; HEALTH CARE COSTS; HUMANS; IMMUNOGLOBULIN G; IMMUNOLOGIC FACTORS; PSORIASIS; RECEPTORS, TUMOR NECROSIS FACTOR; REMISSION INDUCTION;

EID: 78049455141     PISSN: 10188665     EISSN: None     Source Type: Journal    
DOI: 10.1159/000320111     Document Type: Article

References (27)

1. Augustin M, Reich K, Glaeske G, Schaefer I, Radtke M: Comorbidity And Age-Related Prevalence Of Psoriasis - Analysis Of Health Insurance Data In Germany. Acta Derm Venereol 2010; 90: 147-151.
2. Augustin M, Glaeske G, Radtke Ma, Christophers E, Reich K, Schäfer I: Epidemiology And Comorbidity Of Psoriasis In Children. Br J Dermatol 2010; 162: 633-636.
3. Augustin M, Krüger K, Radtke Ma, Schwippl I, Reich K: Disease Severity, Quality Of Life And Health Care In Plaque-Type Psoriasis: A Multicenter Cross-Sectional Study In Germany. Dermatology 2008; 216: 366-372. (Pubitemid 351630108)
4. Schöffski O, Augustin M, Prinz J, Rauner K, Schubert E, Sohn S, Reich K: Krankheitskosten Und Lebensqualität Bei Patienten Mit Mittelschwerer Bis Schwerer Psoriasis Vulgaris In Deutschland: Eine Multizentrische Studie. J Dtsch Dermatol Ges 2007; 5:209-218. (Pubitemid 46361354)
5. Nestle Fo, Kaplan Dh, Barker J: Psoriasis. N Engl J Med 2009; 361: 496-509.
6. Nast A, Kopp Ib, Augustin M, Banditt Kb, Boehncke Wh, Follman M, Friedrich M, Huber M, Kahl C, Klaus J, Koza J, Kreiselmeier I, Mohr J, Mrowietz U, Ockenfels Hm, Orzechowski Hd, Prinz J, Reich K, Rosenbach T, Rosumeck S, Schlaeger M, Schmid- Ott G, Sebastian M, Streit V, Weberschock T, Rzany B: S3-Leitlinie Zur Therapie Der Psoriasis Vulgaris. J Dtsch Dermatol Ges 2006; 4(Suppl 2):S1-S126. (Pubitemid 44832083)
7. Pathirana D, Ormerod Ad, Saiag P, Smith C, Spuls Pi, Nast A, Barker J, Bos Jd, Burmester Gr, Chimenti S, Dubertret L, Eberlein B, Erdmann R, Ferguson J, Girolomoni G, Gisondi P, Giunta A, Griffiths C, Hönigsmann H, Hussain M, Jobling R, Karvonen Sl, Kemeny L, Kopp I, Leonardi C, Maccarone M, Menter A, Mrowietz U, Naldi L, Nijsten T, Ortonne Jp, Orzechowski Hd, Rantanen T, Reich K, Reytan N, Richards H, Thio Hb, Van De Kerkhof P, Rzany B: European S3-Guidelines On The Systemic Treatment Of Psoriasis Vulgaris. J Eur Acad Dermatol Venereol 2009; 23(Suppl 2):5-70.
8. Nelson Aa, Pearce Dj, Fleischer Ab Jr, Balkrishnan R, Feldman Sr: Cost-Effectiveness Of Biologic Treatments For Psoriasis Based On Subjective And Objective Efficacy Measures Assessed Over A 12-Week Treatment Period. Am Acad Dermatol 2008; 58: 125-135. (Pubitemid 350298147)
9. Gordon Kb, Langley Rg, Leonard Cl, Toth D, Mente Ma, Kang S, Et Al: Clinical Response To Adalimumab Treatment In Patients With Moderate To Severe Psoriasis: Doubleblind, Randomized Controlled Trial And Open-Label Extension Study. J Am Acad Dermatol 2006; 55: 598-606. (Pubitemid 44436647)
10. Menter A, Tyring Sk, Gordon K, Kimball Ab, Leonardi C, Langley Rg, Strober Be, Kaul M, Gu Y, Okun M, Papp K: Adalimumab Therapy For Moderate To Severe Psoriasis: A Randomized, Controlled Phase Iii Trial. J Am Acad Dermatol 2008; 58: 106-115. (Pubitemid 350298146)
11. Saurat Jh, Stingl G, Dubertret L, Papp K, Langley Rg, Ortonne Jp, Unnebrink K, Kaul M, Camez A, Champion Study Investigators: Efficacy And Safety Results From The Randomized Controlled Comparative Study Of Adalimumab Vs Methotrexate Vs Placebo In Patients With Psoriasis (Champion). Br J Dermatol 2008; 158: 558-566. (Pubitemid 351239154)
12. Leonardi Cl, Powers Jl, Matheson Rt, Goffe Bs, Zitnik R, Wang A, Et Al: Etanercept As Monotherapy In Patients With Psoriasis. N Engl J Med 2003; 349: 2014-2022. (Pubitemid 37448924)
13. Gottlieb A, Matheson Rt, Lowe N, Krueger Gg, Kang S, Goffe Bs, Et Al: A Randomized Trial Of Etanercept As Monotherapy For Psoriasis. Arch Dermatol 2003; 139: 1627-1632. (Pubitemid 37523083)
14. Papp Ka, Tyring S, Lahfa M, Prinz J, Griffiths Ce, Nakanishi Am, Et Al: A Global Phase Iii Randomized Controlled Trial Of Etanercept In Psoriasis: Safety, Efficacy, And Effect Of Dose Reduction. Br J Dermatol 2005; 152: 1304-1312. (Pubitemid 40933433)
15. Van De Kerkhof Pc, Segaert S, Lahfa M, Luger Ta, Karolyi Z, Kaszuba A, Leigheb G, Camacho Fm, Forsea D, Zang C, Boussuge Mp, Paolozzi L, Wajdula J: Once Weekly Administration Of Etanercept 50 Mg Is Efficacious And Well Tolerated In Patients With Moderate-To-Severe Plaque Psoriasis: A Randomized Controlled Trial With Open-Label Extension. Br J Dermatol 2008; 159: 1177-1185.
16. Gottlieb Ab, Evans R, Li S, Dooley Lt, Guzzo Ca, Baker D, Et Al: Infliximab Induction Therapy For Patients With Severe Plaque-Type Psoriasis: A Randomized, Double-Blind, Placebo- Controlled Trial. J Am Acad Dermatol 2004; 51: 534-542. (Pubitemid 39278071)
17. Reich K, Nestle Fo, Papp K, Ortonne Jp, Evans R, Guzzo C, Et Al: Infliximab Induction And Maintenance Therapy For Moderate Tosevere Psoriasis: A Phase Iii, Multicentre, Double- Blind Trial. Lancet 2005; 366: 1367-1374.
18. Menter A, Feldman Sr, Weinstein Gd, Papp K, Evans R, Guzzo C, Et Al: A Randomized Comparison Of Continuous Vs Intermittent Infliximab Maintenance Regimens Over 1 Year In The Treatment Of Moderate-To-Severe Plaque Psoriasis. J Am Acad Dermatol 2007; 56: 31.E1-31.E15. (Pubitemid 44969297)
19. Leonardi Cl, Kimball Ab, Papp K A, Yeilding N, Guzzo C, Wang Y, Li S, Dooley Lt, Gordon Kb, Phoenix 1 Study Investigators: Efficacy And Safety Of Ustekinumab, A Human Interleukin-12,23 Monoclonal Antibody, In Patients With Psoriasis: 76-Week Results From A Randomised, Double-Blind, Placebo- Controlled Trial (Phoenix 1). Lancet 2008; 371: 1665-1674. (Pubitemid 351671883)
20. Papp Ka, Langley Rg, Lebwohl M, Krueger Gg, Szapary P, Yeilding N. Guzzo C, Hsu Mc, Wang Y, Li S, Dooley Lt, Reich K, Phoenix 2 Study Investigators: Efficacy And Safety Of Ustekinumab, A Human Interleukin-12,23 Monoclonal Antibody, In Patients With Psoriasis: 52-Week Results From A Randomised, Double- Blind, Placebo-Controlled Trial (Phoenix 2). Lancet 2008; 371: 1675-1684. (Pubitemid 351671884)
21. Verhagen Ap, De Vet Hc, De Bie Ra, Kessels Ag, Boers M, Bouter Lm, Et Al: The Delphi List: A Criteria List For Quality Assessment Of Randomized Clinical Trials For Conducting Systematic Reviews Developed By Delphi Consensus. J Clin Epidemiol 1998; 51: 1235-1241. (Pubitemid 29009523)
22. Briggs Ah, Gray Am: Handling Uncertainty In Economic Evaluations Of Healthcare Interventions. Bmj 1999; 319: 635-638. (Pubitemid 29414568)
23. Oecd: Purchasing Power Parities, Principaux Indicateurs économiques. Http://Www. Oecd.Org/Dataoecd/61/54/18598754.Pdf (Accessed April 23, 2010).
24. Greiner W, Schöffski O, Graf Von Der Schulenburg Jm: Die übertragbarkeit Internationaler Ergebnisse Auf Nationale Fragestellungen; In Schöffski O, Graf Von Der Schulenburg Jm (Eds): Gesundheitsö konomische Evaluationen. Berlin, Springer, 2007.
25. Farahani P, Levine M, Goeree R: A Comparison Between Integrating Clinical Practise Setting And Randomized Clinical Trial Setting Into Economic Evaluation Models Of Therapeutics. J Eval Clin Pract 2006: 12463-12470. (Pubitemid 44126798)
26. Zink A, Strangfeld A, Schneider M, Herzer P, Hierse F, Stoyanova-Scholz M, Wassenberg, S. Kapelle A, Listing J: Effectiveness Of Tumor Necrosis Factor Inhibitors In Rheumatoid Arthritis In An Observational Cohort. Arthritis Rheum 2006; 54: 3399-3407.
27. Augustin M, Radtke Ma, Zschocke I, Blome C, Behechtnejad J, Schäfer I, Reusch M, Mielke V, Rustenbach Sj: The Patient Benefit Index: A Novel Approach In Patient-Defined Outcomes Measurement For Skin Diseases. Arch Dermatol Res 2009: 301: 561-571.